Abstract
Introduction: Uremic pruritus is a common symptom in patients with end-stage renal disease (ESRD). Intense pruritus can lead to uncontrollable scratching, impaired sleep, anxiety, depression, therefore significantly lowering patient's life quality. Although the prevalence of uremic itch in patients on dialysis has declined over time, it is still present in peritoneal dialysis (PD) and hemodialysis (HD) patients. Aim: The aim of this study is to investigate the prevalence of pruritus in HD patients compared to PD patients, as well as possible differences in its presentation and correlation with demographic and clinical characteristics of the population. Material and methods: A total of 50 HD and 50 PD patients were included. Dialysis modality, patient demographic, clinical characteristics, and laboratory data were recorded. Data on the presence and duration of itching, skin dryness and scaling were obtained from a general itch questionnaire. The visual-analogue scale (VAS) and the 5-D itch scale were used for evaluation of pruritus. Results: Pruritus was present in 42% of PD patients and 24% of HD patients (p = 0.056), without statistically significant differences in the distribution and intensity of pruritus in patients on different dialysis modality. A significantly higher number of PD patients had dry (41 vs 31; p = 0.026) and scaling skin (31 vs 15; p = 0.001). Patients with pruritus in PD had significantly higher levels of intact parathyroid hormone (iPTH) (386.57±302.29 pg/mL vs 159.25±163.52 pg/mL; p = 0.033) and AST (23.84±11.36 U/L vs 14.7±3.73 U/L; p=0,002), while having significantly lower levels of urea (18.78±7.60 mmol/L vs 23.65±4,31 mmol/L; p=0.028), creatinine (717.96 ± 229.50 mmol/L vs 940.06±207.57 mmol/L; p=0.009) and potassium (4.17 ± 0,63 mmol/L vs 5.80 ± 0.80 mmol/L; p = 0.000) in comparison to HD patients with pruritus. Conclusion: Pruritus is a common symptom among ESRD patients treated with dialysis. In our study, a higher prevalence of pruritus was observed in PD patients. Dry skin and higher levels of iPTH have been singled out as possible contributing factors to the occurrence of itch.
Highlights
Uremic pruritus is a common symptom in patients with end-stage renal disease (ESRD)
Rezultati: Pruritus je bio prisutan kod 42% ispitanika na peritoneal dialysis (PD) i 24% ispitanika na HD (p = 0,056), bez statistički značajne razlike u distribuciji i intenzitetu pruritusa kod bolesnika lečenih različitim modalitetima dijalize
Svi ispitanici su dobrovoljno pristali da učestvuju u istraživanju i nakon što su detaljno informisani o protokolu i svrsi studije dali su svoju pisanu saglasnost za učestvovanje u ispitivanju
Summary
Uremic pruritus is a common symptom in patients with end-stage renal disease (ESRD). Intense pruritus can lead to uncontrollable scratching, impaired sleep, anxiety, depression, significantly lowering patient’s life quality. Vuksanović S. et al Prevalencija i karakteristike pruritusa kod bolesnika lečenih različitim metodama dijalize. Intenzivan pruritus može dovesti do nekontrolisanog češanja, nesanice, anksioznosti, depresije, a time i značajnog poremećaja kvaliteta života bolesnika. Rezultati: Pruritus je bio prisutan kod 42% ispitanika na PD i 24% ispitanika na HD (p = 0,056), bez statistički značajne razlike u distribuciji i intenzitetu pruritusa kod bolesnika lečenih različitim modalitetima dijalize. Zaključak: Svrab je često prisutan kod bolesnika sa terminalnom slabošću bubrega lečenih dijalizama. Hronični pruritus je često prisutan neprijatan simptom kod bolesnika sa terminalnim stadijumom bubrežne slabosti i označava se kao uremijski pruritus [3]. Iako je učestalost prisustva pruritusa kod osoba sa terminalnom uremijom na dijaliznom lečenju u izvesnom padu, on je i dalje prisutan kod bolesnika lečenih dijalizama [5, 10]. Ciljevi istraživanja su bili da se ispita zastupljenost svraba u grupi bolesnika na HD u odnosu na bolesnike koji se leče PD, te da se utvrdi postojanje razlike u načinu manifestacije svraba i povezanosti svraba sa demografskim i kliničkim karakteristikama ispitivane populacije
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.